文献速递慢性肾脏病

NAD增强治疗糖尿病肾病:随机对照试验方案

Nicotinamide Adenine Dinucleotide Augmentation in Diabetic Kidney Disease: Randomized Trial Study Protocol.
PubMed 文献 · Kidney Int Rep · 2026-07-16

糖尿病肾病(DKD)是全球慢性肾脏病和肾衰竭的主要原因,NAD水平降低与DKD发病机制相关。本试验为2a期、随机、多中心、双盲、安慰剂对照、平行组研究,评估口服β-NMN(MIB-626)在DKD成人中的疗效与安全性。

要点

  • NAD前体NMN在临床前模型中可减轻白蛋白尿和肾损伤。
  • 该2a期试验评估口服MIB-626对DKD患者UACR的影响。
  • 入组标准为糖尿病、UACR≥100 mg/g且eGFR>25 ml/min/1.73m2。

核心结论

  • 该2a期试验旨在评估NAD增强改善白蛋白尿性DKD患者UACR的安全性和有效性。
  • 结果将提示NAD增强是否值得在更大规模的、以长期肾脏结局为终点的试验中进一步评估。

研究设计与样本

  • 2a期、随机、多中心、双盲、安慰剂对照、平行组研究。
  • 随机接受口服药物级微晶β-NMN(MIB-626)1000 mg每日两次或安慰剂治疗24周,随后12周干预后随访。
  • 随机化按生物学性别、年龄(30-44、45-65和≥66岁)和入组中心分层。

关键数值与推荐

  • 主要终点为从基线至24周UACR的变化。
  • 次要结局包括血清肌酐、胱抑素C和eGFR、肾损伤和生物学年龄生物标志物、血糖控制、肌肉性能和身体功能指标以及循环NAD代谢组。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Diabetic kidney disease (DKD) is the leading cause of chronic kidney disease (CKD) and kidney failure worldwide. Reduced nicotinamide adenine dinucleotide (NAD) levels are mechanistically linked to DKD pathogenesis; and NAD augmentation by administration of its precursor, nicotinamide mononucleotide (NMN), has attenuated albuminuria and kidney injury in preclinical models. METHODS: The NAD Augmentation in Diabetic Kidney Disease (NAD in DKD) trial is a phase 2a, randomized, multicenter, double-blind, placebo-controlled, parallel-group study evaluating the efficacy and safety of oral pharmaceutical-grade microcrystalline β-NMN (MIB-626) in adults with DKD. One hundred fifty-six participants aged ≥ 30 years with diabetes, urinary albumin-to-creatinine ratio (UACR) ≥ 100 mg/g, and estimated glomerular filtration rate (eGFR) > 25 ml/min per 1.73 m2 were randomized to receive MIB-626 (1000 mg twice daily) or placebo for 24 weeks, followed by 12 weeks of postintervention follow-up. The randomization was stratified for biological sex, age (30-44, 45-65, and ≥ 66 years), and enrolling site. The primary end point was change in UACR from baseline to 24 weeks. Secondary outcomes included serum creatinine, cystatin C, and eGFR, biomarkers of kidney injury and biological age, glycemic control, measures of muscle performance and physical function, and the circulating NAD metabolome. CONCLUSION: This phase 2a trial was designed to evaluate the safety and efficacy of NAD augmentation in improving UACR in albuminuric DKD. The results will inform whether NAD augmentation warrants further evaluation in larger trials statistically powered for long-term kidney outcomes. The study is registered at ClinicalTrials.gov (NCT05759468).

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Chandra MS, Gagliano-Jucá T, Shekhar S, et al. Nicotinamide Adenine Dinucleotide Augmentation in Diabetic Kidney Disease: Randomized Trial Study Protocol. Kidney Int Rep. 2026. PMID: 42603990. doi:10.1016/j.ekir.2026.106700

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。